TEST STRIPS AND COLOR CHART, BILIRUBIN, BL

The contract solicitation SPE2DS-26-T-256B seeks the procurement of urine test strips and color charts capable of detecting bilirubin, blood, glucose, ketone, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen, with the unit of issue being a bottle containing 100 strips. Delivery is required within 20 days after award to FPO 96664 aboard the USNS AMELIA EARHART T-AKE 6, under FOB Destination terms, meaning the contractor assumes all risk until delivery. The item, identified by NSN 6550-01-221-5400, is a Type I Code K medical supply with a non-extendable shelf life of 18 months, and no more than two months may have elapsed from the date of manufacture to the date of delivery. All packaging and labeling must comply with Medical Marking Standard No. 1, Revision C, superseding MIL-STD-129, and must clearly display the date of manufacture, expiration date, contract number, and lot number. Packaging must adhere to DLA Packaging Requirements RP001 and ASTM D3951 for non-hazardous materials, with hazardous materials subject to TQ Requirement IP025 and the Hazard Communication Standard, requiring submission of compliant Safety Data Sheets prior to award. The contract mandates full compliance with DFARS and FAR requirements including electronic invoicing through WAWF, safeguarding of covered defense information via NIST SP 800-171 and 252.204-7012, and adherence to clauses addressing trafficking in persons, employment eligibility, sustainable products, and whistleblower rights. Offerors must hold a valid Unique Entity ID and CAGE code and represent their size status, with potential socioeconomic program eligibility disclosures required if applicable. The solicitation is administered by the Department of Defense, Medical Supply Chain MD SURG FSF, with Mary-Kathryn Donahue as the primary point of contact, and submissions must be made exclusively via the DIBBS portal by July 27, 2026. The contract includes provisions for accelerated payments to small business subcontractors, unenforceability of unauthorized obligations, and modification pricing, and reflects deviations from standard clauses to align with current agency policy as of February 2026.